Rates of Serious Infections in HIV-Infected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases.

scientific article published on 22 June 2016

Rates of Serious Infections in HIV-Infected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/ACR.22955
P932PMC publication ID5179316
P698PubMed publication ID27332039

P50authorColin B LigonQ57323447
P2093author name stringLydia Gedmintas
Marisa Tungsiripat
Leonard Calabrese
Sintawat Wangsiricharoen
Clifton Bingham
Carlos Lozada
Admad Dehrab
P2860cites workLife expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesQ24597052
The rising challenge of non-AIDS-defining cancers in HIV-infected patientsQ26861496
A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registriesQ34216770
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphomaQ35511780
Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of diseaseQ36330070
Septic shock after seasonal influenza vaccination in an HIV-infected patient during treatment with etanercept for rheumatoid arthritis: a case reportQ36826300
Liver and kidney transplantation in HIV-infected patients.Q37639166
Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS.Q38698940
A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosisQ38882228
Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1.Q40936133
Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritisQ44877235
HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomesQ46757223
Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2Q74343625
The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic diseaseQ80197399
Pulmonary and nodal tuberculosis in a patient with inflammatory bowel disease and HIV infection treated with infliximabQ82963639
P433issue3
P304page(s)449-452
P577publication date2017-03-01
P1433published inArthritis Care and ResearchQ15754720
P1476titleRates of Serious Infections in HIV-Infected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases
P478volume69

Reverse relations

cites work (P2860)
Q91977839Human immunodeficiency virus infection (HIV)-associated rheumatic manifestations in thepre- and post-HAART eras
Q33613493Targeting TNF and TNF Receptor Pathway in HIV-1 Infection: from Immune Activation to Viral Reservoirs